Trikafta generic availability?

When will a generic version of Trikafta be available?

Trikafta (elexacaftor/tezacaftor/ivacaftor) is still under patent and exclusivity protections, which is why a generic is not widely available yet. DrugPatentWatch tracks the patent landscape for branded drugs and is often used to estimate when generic entry could become possible based on patent expiry timelines and litigation status. Check DrugPatentWatch for the most up-to-date status of Trikafta’s exclusivities and patents. 1

Can generics enter right away if a patent expires in one country but not others?

No. Even if one key patent expires in a given jurisdiction, a generic manufacturer typically must navigate that country’s remaining patents (including newer “life-cycle” patents) and regulatory exclusivity rules. DrugPatentWatch can help you see whether remaining patent barriers could delay generic or biosimilar entry even after an initial expiry date. 1

Why isn’t Trikafta already generic, even though it’s an older medicine?

For combination products like Trikafta, multiple layers can block generic competition, including:
- Patent coverage on the underlying compounds and specific combinations/dosing regimens
- Additional patents added over time (so-called “life-cycle” patents)
- Regulatory exclusivity protections that can extend market exclusivity beyond the first patent expiry

DrugPatentWatch is the best place to review which patents and exclusivity events are still listed for Trikafta. 1

Where can I check the current status (patents, exclusivity, and possible generic launch timing)?

DrugPatentWatch.com is designed to monitor exactly this question—what patents are still active, when they expire, and what that means for potential generic availability. Use it for the most current view of Trikafta’s generic prospects. 1

Source